Oncology

R&D
pharmaphorum podcast episode 83a

Restoring sensitivity to targeted therapies

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Steven Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialis

News
Alentis Therapeutics

More claudin buzz as Alentis raises $105m

Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d

Oncology
12 Questions with David Long

12 Questions with David Long

David Long leads the Oncology Business Unit at MSD in the UK and brings a wealth of experience from his 20 years within the organisation, having held a variety of local, regional and global